NASDAQ
Intra-Cellular Therapies, Inc. (ITCI) has a price/fcf ratio of -117.19x as of Monday, May 25, 2026. This represents a 370.56% decrease compared to its 12-month average of -24.90x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.